PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
WULF vs. SRPT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between WULF and SRPT is 0.04, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.0

Performance

WULF vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TeraWulf Inc. (WULF) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%150.00%200.00%250.00%NovemberDecember2025FebruaryMarchApril
-14.60%
58.74%
WULF
SRPT

Key characteristics

Sharpe Ratio

WULF:

0.08

SRPT:

-0.91

Sortino Ratio

WULF:

1.00

SRPT:

-1.43

Omega Ratio

WULF:

1.11

SRPT:

0.79

Calmar Ratio

WULF:

0.10

SRPT:

-0.80

Martin Ratio

WULF:

0.29

SRPT:

-2.14

Ulcer Index

WULF:

32.28%

SRPT:

24.33%

Daily Std Dev

WULF:

115.87%

SRPT:

57.35%

Max Drawdown

WULF:

-98.50%

SRPT:

-98.17%

Current Drawdown

WULF:

-92.02%

SRPT:

-65.36%

Fundamentals

Market Cap

WULF:

$1.10B

SRPT:

$6.01B

EPS

WULF:

-$0.21

SRPT:

$2.34

Total Revenue (TTM)

WULF:

$97.62M

SRPT:

$1.49B

Gross Profit (TTM)

WULF:

$49.42M

SRPT:

$1.21B

EBITDA (TTM)

WULF:

-$28.91M

SRPT:

$247.43M

Returns By Period

The year-to-date returns for both investments are quite close, with WULF having a -49.12% return and SRPT slightly higher at -49.08%. Over the past 10 years, WULF has underperformed SRPT with an annualized return of -14.41%, while SRPT has yielded a comparatively higher 15.87% annualized return.


WULF

YTD

-49.12%

1M

-31.26%

6M

-33.49%

1Y

18.52%

5Y*

1.29%

10Y*

-14.41%

SRPT

YTD

-49.08%

1M

-42.00%

6M

-49.39%

1Y

-51.78%

5Y*

-8.43%

10Y*

15.87%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

WULF vs. SRPT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WULF
The Risk-Adjusted Performance Rank of WULF is 5959
Overall Rank
The Sharpe Ratio Rank of WULF is 5555
Sharpe Ratio Rank
The Sortino Ratio Rank of WULF is 6767
Sortino Ratio Rank
The Omega Ratio Rank of WULF is 6262
Omega Ratio Rank
The Calmar Ratio Rank of WULF is 5858
Calmar Ratio Rank
The Martin Ratio Rank of WULF is 5656
Martin Ratio Rank

SRPT
The Risk-Adjusted Performance Rank of SRPT is 66
Overall Rank
The Sharpe Ratio Rank of SRPT is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 88
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 77
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 77
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

WULF vs. SRPT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for TeraWulf Inc. (WULF) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for WULF, currently valued at 0.08, compared to the broader market-2.00-1.000.001.002.003.00
WULF: 0.08
SRPT: -0.91
The chart of Sortino ratio for WULF, currently valued at 1.00, compared to the broader market-6.00-4.00-2.000.002.004.00
WULF: 1.00
SRPT: -1.43
The chart of Omega ratio for WULF, currently valued at 1.11, compared to the broader market0.501.001.502.00
WULF: 1.11
SRPT: 0.79
The chart of Calmar ratio for WULF, currently valued at 0.10, compared to the broader market0.001.002.003.004.005.00
WULF: 0.10
SRPT: -0.80
The chart of Martin ratio for WULF, currently valued at 0.29, compared to the broader market-5.000.005.0010.0015.0020.00
WULF: 0.29
SRPT: -2.14

The current WULF Sharpe Ratio is 0.08, which is higher than the SRPT Sharpe Ratio of -0.91. The chart below compares the historical Sharpe Ratios of WULF and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.00NovemberDecember2025FebruaryMarchApril
0.08
-0.91
WULF
SRPT

Dividends

WULF vs. SRPT - Dividend Comparison

Neither WULF nor SRPT has paid dividends to shareholders.


TTM2024202320222021
WULF
TeraWulf Inc.
0.00%0.00%0.00%0.00%33.22%
SRPT
Sarepta Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%

Drawdowns

WULF vs. SRPT - Drawdown Comparison

The maximum WULF drawdown since its inception was -98.50%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for WULF and SRPT. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2025FebruaryMarchApril
-92.02%
-65.36%
WULF
SRPT

Volatility

WULF vs. SRPT - Volatility Comparison

The current volatility for TeraWulf Inc. (WULF) is 34.49%, while Sarepta Therapeutics, Inc. (SRPT) has a volatility of 36.36%. This indicates that WULF experiences smaller price fluctuations and is considered to be less risky than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
34.49%
36.36%
WULF
SRPT

Financials

WULF vs. SRPT - Financials Comparison

This section allows you to compare key financial metrics between TeraWulf Inc. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab